SUMMARY Recent studies have suggested that patients with multiple endocrine neoplasia type I (MEN I) may have abnormal serum gastrin secretion in the absence of gastrin producing tumours. G-(gastrin) cell function by three provocation tests in 20 patients with hyperparathyroidism from six MEN I-families were studied: each patient was an obligate carrier of the MEN I-gene. The serum gastrin response to secretin was used to identify the presence of gastrinoma, that to a test meal of G-cell hyperfunction of the antral and/or duodenal mucosa, and that to bombesin to differentiate antral from duodenal G-cell hyperfunction. Seven patients had basal hypergastrinaemia and hyperchlorhydria. These patients had increased serum gastrin responses to secretin (p<0-01) and to bombesin (p<0'02), but normal postprandial responses. In the 13 normogastrinaemic patients the responses to the three stimuli were normal. In families with MEN
Multiple endocrine neoplasia type I (MEN-I) is an autosomal dominant inherited disorder characterised principally by tumours of the parathyroid glands, the pituitary, and the pancreatic islets.' Less common are tumours of the adrenal cortex and various types of carcinoids. An individual carrying the MEN-I gene may have one or any combination of these tumours. In such patients hypergastrinaemia is usually caused by gastrin producing tumours leading to marked gastric hypersecretion and severe ulcer, the Zollinger-Ellison syndrome. Other abnormalities of gastrin secretion have recently been described, however, in patients with the MEN I-syndrome without gastrin producing tumours. Such patients showed an enlarged serum gastrin response to a standard test meal suggesting hyperplasia or hyperfunction of antroduodenal G-(gastrin) cells. In this respect it is interesting to note that Friesen et al have described hyperplasia of G-cells in the antral mucosa of members of MEN I-families in association with the development of clinical endocrinopathies.' This finding may indicate that hypergastrinaemia of antral origin could be a distinct phenotypic manifestation of the MEN I-gene. Furthermore, antral G-cell hyperplasia and raised serum gastrin concentrations have been described in hyperparathyroidism,""' while antral G-cell hyperplasia has also been reported in patients with acromegaly,' disorders that can be components of the MEN I syndrome.
The present study was undertaken to characterise G-cell function in patients who were obligate carriers of the MEN I-gene, as determined by their being members of families with well characterised MEN-I and also having evidence of hyperparathyroidism.
Methods

PATIENTS
The subjects consisted of 20 patients with hyperparathyroidism originating from six families with MEN I. Family members who had undergone prior gastric surgery were excluded from this study. The patients and families were ascertained in a population genetic study of 10 Zollinger-Ellison patients (for the complete pedigrees, see ref 6) . In that study a total of 109 family members, including all living first 1358
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Results
Seven of the 20 patients, five women, had basal hypergastrinaemia on all three occasions (cases [1] [2] [3] [4] [5] [6] [7] in the Table) . There were no significant differences between the hypergastrinaemic and normogastrinaemic patients in age (44 (9) (Fig. 1) . When expressed as percentage change over basal, the patients with basal hypergastrinaemia had a significantly (p<0-01) lower increase (Fig. 2) , but there was considerable overlap between the groups. Case 9 is of particular interest because of the markedly exaggerated serum gastrin response to feeding (Table) . Bombesin infusion induced an increase in serum gastrin in all patients studied. The mean increase was significantly greater (p<0-02) in the hypergastrinaemic patients (Fig. 1) , but when the results were expressed as percentage of basal, the hypergastrinaemic patients had a significantly lower (p<0.01) percentage increment in serum gastrin after bombesin (Fig. 2) . 23 The results of this study indicate that in obligate carriers of the MEN I-gene the measurement of basal serum gastrin concentrations is an excellent discriminant between the patients with and without gastrin producing tumours. In seven of the individuals serum gastrin was raised on all three occasions, whereas in the other 13 patients serum gastrin was repeatedly normal. It can be argued that the presence of gastrinomas has not been histologically proven in all seven hypergastrinaemic patients, and that a pancreatic tumour has not definitely been ruled out in the other 13 patients. There was no clinical indication, however, for undertaking laparotomy in these patients. First, because the hypergastrinaemic patients were effectively treated with histamine H2-receptor antagonists (cimetidine or ranitidine) or omeprazole, obviating the need for total gastrectomy,24125 and, second, because it is generally accepted that, because of multiplicity of tumours, attempts to curatively resect the gastrin producing tumours in MEN I-patients are unsuccessful.2627 Furthermore, all hypergastrinaemic patients had markedly increased basal gastric acid secretion, whereas such hypersecretion of gastric acid was excluded in the two normogastrinaemic patients with gastric complaints. The results of this study, showing normal basal serum gastrin concentrations in hyperparathyroid patients without gastrin producing tumours, contrast with two recent reports indicating basal hypergastrinaemia in 22 and 25% of such patients.'2'3 This discrepancy is not because of the characteristics of the gastrin assay used in this study, as it has been shown that the gastrin antiserum used has equal binding to all known sulphated and nonsulphated carboxy-terminal forms of gastrin.'6 Furthermore, the discrepancy is not due to the fact that in our study only patients with MEN Ihyperparathyroidism were investigated, as we have previously reported normal serum gastrin concentrations in patients with non-MEN 1-hyperparathyroidism and in those with non-hyperparathyroid hypercalcaemia. 28 The serum gastrin increment after secretin was above 200 pg/ml in all hypergastrinaemic MEN Ipatients, but the response was modest in all but one of the normogastrinaemic patients. In the latter patient, however (case 19) with an increment of 101 pg/mI there was not gastric hypersecretion or CTevidence of pancreatic tumours, and serum gastrin concentrations remained normal during a follow up of more than three years. Therefore, this study confirms previous reports indicating that an exaggerated serum gastrin response to secretin is highly specific for gastrin producing tumours in MEN Ipatients with combined basal hypergastrinaemia and hyperchlorhydria.'56 In this respect, it is noteworthy that in patients with gastrinoma the serum gastrin response to secretin is influenced by the serum calcium concentration.29"' In fact, acute hypercalcaemia enhances, while acute hypocalcaemia reduces the serum gastrin secretion after secretin provocation in patients with Zollinger-Ellison syndrome. 29 On the other hand hypercalcaemia induced by infusion of calcium, did not induce false positive secretin provocation tests in peptic ulcer patients without gastrinoma.29 Furthermore, normalisation of serum calcium by parathyroidectomy in MEN Ipatients with combined hyperparathyroidism and Zollinger-Ellison syndrome diminished secretin induced serum gastrin secretion.`Another interesting finding of the present study is that the absolute amount of gastrin released from the antroduodenal mucosa after a meal is normal in MEN I-patients independent of the presence of hyper-or normogastrinaemia. This is remarkable because a reduced gastrin secretion would have been anticipated in the presence of gastric hypersecretion in the patients with gastrinomas. This finding may indicate an impaired feedback mechanism between gastric acid and antral gastrin secretion in such patients. Skogseid et al7 have studied the serum gastrin response to feeding in a single MEN I-patient with basal hypergastrinaemia, but the large variation in postprandial serum gastrin concentrations precluded a definite conclusion. The present finding of normal postprandial gastrin secretion in the normogastrinemic MEN I-patients is in contrast with the aforementioned study of Skogseid et al, 7 showing an enlarged serum gastrin response to feeding in such patients. Analysis of the data, however, shows that in the latter study exaggerated postprandial serum gastrin secretion occurred in only five of the 12 patients studied and that the mean basal serum gastrin concentration in the 'normogastrinaemic' MEN I-patients was significantly higher than in the control group. In this respect it may be interesting to note that the single normogastrinaemic patient with an enlarged postprandial serum gastrin response in the present study (case 9) had a relatively high basal serum gastrin concentration when compared with the other normogastrinaemic patients. In this patient achlorhydria was excluded as the cause of the increased post-prandial gastrin secretion by the finding of a slightly raised serum pepsinogen I level of 126 ng/ml. Skogseid et al7 suggested that the exaggerated serum gastrin response to the meal in normogastrinaemic MEN I-patients was caused by islet-cell hyperplasia of the pancreas. Because the serum gastrin response to feeding is accepted to be a reliable measure of the G-cell function of the antroduodenal mucosa, however, antral G-cell hyperfunction is a more likely explanation.'78 Antral G-cell hyperplasia has been described by Friesen in a family with the MEN Isyndrome, but this author did not report whether the antral G-cell hyperplasia in antral biopsies was accompanied by an exaggerated postprandial serum gastrin secretion.89 This hyperplasia appears to be restricted to certain families and surprisingly appears to occur in both affected and otherwise unaffected members.89 It should, however, be realised that the diagnosis of antral G-cell hyperplasia, established by G-cell counting of these cells in antral mucosal biopsies, may not accurately reflect overall G-cell function because of the variable size of the antrum and patchy distribution of G-cells.'7 Antral G-cell hyperplasia has also been described in hyperparathyroidism,"' but Skogseid et al7 found a normal postprandial serum gastrin secretion in four hyperparathyroidism who had no evidence of the MEN Isyndrome. The present study, however, clearly indicates that antral G-cell hyperfunction is not a frequent manifestation of the MEN I-syndrome and thus that neither the MEN I-syndrome per se nor the hypercalcaemia of hyperparathyroidism affects the G-cell function. This finding was supported by the absence of an increased serum gastrin response to infusion of bombesin in the normogastrinaemic MEN I-patients. Because bombesin is reported to release gastrin selectively from the antral and not from the duodenal mucosa," it is suggested to be a more specific stimulus of gastrin secretion by the antral Gcells than a meal. In fact, it has been shown that the serum gastrin response to bombesin can be used to accurately identify hyperfunction and hypofunction of antral G-cells.2' The present study, however, indicates that an enlarged serum gastrin response to bombesin is not specific for antral G-cell hyperfunction but also occurs in patients with gastrin producing tumours. It has recently been shown that the gastrin secretion induced by bombesin in patients with gastrinoma is probably because of a direct stimulation of gastrin secretion from the tumour, as bombesin increases gastrin release from gastrinoma cells in longterm culture. 3' In conclusion, the main findings of the present study were as follows: (i) gastrinoma was the only endocrine disorder in MEN I accounting for abnormal gastrin secretion, (ii) repeated measurements of basal serum gastrin could readily identify patients with gastrinoma in MEN I-families, provided that achlorhydria had been excluded, (iii) antral G-cell hyperfunction was not a frequent manifestation of the MEN I-syndrome, and (iv) bombesin was not a specific stimulus of antral gastrin secretion but also released gastrin from tumours in hypergastrinaemic MEN I-patients. 
